Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site. # Synthekine ## Sitemaps - [XML Sitemap](https://www.synthekine.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies](https://www.synthekine.com/news/synthekine-doses-first-patient-in-phase-1-clinical-trial-of-orthogonal-il-2-and-cd19-car-t-combination-therapy-stk-009-syncar-001-for-treatment-of-cd19-hematologic-malignancies/) - [Synthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive Officer](https://www.synthekine.com/news/synthekine-appoints-veteran-biotech-leader-susan-m-molineaux-ph-d-as-chief-executive-officer/) - Synthekine, Inc., a clinical-stage biotechnology company developing precision cytokine therapeutics, today announced the appointment of Susan M. Molineaux, Ph.D., as Chief Executive Officer. - [Sr. Clinical Trial Manager](https://www.synthekine.com/careers/sr-clinical-trial-manager/) - [Synthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK-012 in First-Line Non-Squamous NSCLC in Oral Presentation at AACR 2026](https://www.synthekine.com/news/synthekine-presents-updated-clinical-and-translational-data-demonstrating-strong-activity-for-stk-012-in-first-line-non-squamous-nsclc-in-oral-presentation-at-aacr-2026/) - [Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK 012 in First Line Nonsquamous NSCLC with Features of Immunotherapy Resistance](https://www.synthekine.com/news/synthekine-announces-aacr-2026-oral-presentation-of-updated-phase-1a-1b-clinical-and-translational-data-for-stk-012-in-first-line-nonsquamous-nsclc-with-features-of-immunotherapy-resistance/) - [Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer](https://www.synthekine.com/news/synthekine-announces-clinical-trial-collaboration-with-merck-to-evaluate-stk-012-in-combination-with-keytruda-pembrolizumab-and-chemotherapy-in-ongoing-randomized-phase-2-trial-in-first-line/) - [Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors](https://www.synthekine.com/news/synthekine-appoints-biotechnology-and-pharmaceutical-industry-veteran-john-a-orwin-as-chair-of-its-board-of-directors/) - [First Patient Dosed in SYNERGY-101, a Global, Randomized Phase 2 Clinical Trial of STK-012 in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer](https://www.synthekine.com/news/first-patient-dosed-in-synergy-101-a-global-randomized-phase-2-clinical-trial-of-stk-012-in-first-line-pd-l1-negative-nonsquamous-non-small-cell-lung-cancer/) - - STK-012 is an α/β biased IL-2 partial agonist designed to stimulate antigen-activated T cells while avoiding IL-2 associated toxicities - Positive Phase 1b data recently presented at SITC 2025, with a 50% response rate in PD-L1 negative non-squamous NSCLC patients, comparing favorably to 23 – 32% response rate expected with standard of care - [Associate Director/ Director, Supply Chain Management](https://www.synthekine.com/careers/associate-director-director-supply-chain-management/) - [Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer](https://www.synthekine.com/news/synthekine-presents-positive-initial-results-from-phase-1a-1b-clinical-trial-of-stk-012-plus-pembrolizumab-and-chemotherapy-in-first-line-pd-l1-negative-nonsquamous-non-small-cell-lung-cancer/) - - 53% response rate in PD-L1 negative patients, comparing favorably to historical response of 23-32% with standard of care chemoimmunotherapy - 60% response rate in 10 patients with STK11, KEAP1, and/or SMARCA4 mutations - STK-012 combined with pembrolizumab and chemotherapy well tolerated with no significant IL-2 toxicities - SYNERGY-101, a global, randomized Phase 2 study of SoC ± STK-012 in PD-L1 negative nonsquamous NSCLC, has been initiated - [Synthekine Announces Late-Breaking Oral Presentation of Initial Clinical Data of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous NSCLC at SITC 2025 Annual Meeting](https://www.synthekine.com/news/synthekine-announces-late-breaking-oral-presentation-of-initial-clinical-data-of-stk-012-plus-pembrolizumab-and-chemotherapy-in-first-line-pd-l1-negative-nonsquamous-nsclc-at-sitc-2025-annual-meeting/) - - STK-012 is an α/β biased IL-2 designed to specifically stimulate antigen activated T cells - Results from an ongoing Phase 1a/1b to be presented at SITC - Company will also present new preclinical data on combinations of STK-012 with T cell engagers - [Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting](https://www.synthekine.com/news/synthekine-presents-positive-initial-results-from-phase-1-clinical-trial-of-cd19-car-t-syncar-001-and-orthogonal-il-2-stk-009-combination-therapy-for-treatment-of-hematologic-malignancies-at-ash-2/) - Synthekine Inc., an engineered cytokine therapeutics company, today announced positive initial results from a first-in-human Phase 1 study (NCT05665062) of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ hematologic malignancies. - [Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024](https://www.synthekine.com/news/synthekine-to-present-preclinical-data-for-cd19-car-t-syncar-001-empowered-by-orthogonal-il-2-stk-009-without-lymphodepletion-at-american-college-of-rheumatology-acr-convergence-2024/) - Synthekine Inc., an engineered cytokine therapeutics company, today announced promising preclinical results with the murine version of its STK-009 + SYNCAR-001 program will be presented at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. - [Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting](https://www.synthekine.com/news/synthekine-announces-presentation-of-new-translational-data-from-phase-1a-1b-clinical-trial-of-α-β-biased-il-2-stk-012-at-the-society-for-immunotherapy-of-cancer-sitc-39th-annual-meeting/) - Synthekine Inc., an engineered cytokine therapeutics company, today presented positive translational results from the Phase 1a dose escalation portion of a Phase 1a/1b clinical trial of its first-in-class α/β-IL-2R biased partial agonist, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston. - [Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion](https://www.synthekine.com/news/synthekine-granted-u-s-fda-fast-track-designation-for-cd19-car-t-and-orthogonal-il-2-investigational-therapy-syncar-001-stk-009-for-the-treatment-of-lupus-without-lymphodepletion/) - [Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, for Treatment of Advanced Solid Tumors](https://www.synthekine.com/news/synthekine-presents-positive-initial-results-from-phase-1a-1b-clinical-trial-of-α-β-biased-il-2-stk-012-for-treatment-of-advanced-solid-tumors/) - [Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion](https://www.synthekine.com/news/synthekine-announces-u-s-fda-clearance-of-ind-application-for-cd19-car-t-and-orthogonal-il-2-combination-therapy-syncar-001-stk-009-for-treatment-of-lupus-without-lymphodepletion/) - [Synthekine Announces Presentation of Initial Results from Phase 1a/1b Clinical Trial of STK-012 at AACR 2024 Annual Meeting](https://www.synthekine.com/news/synthekine-announces-presentation-of-initial-results-from-phase-1a-1b-clinical-trial-of-stk-012-at-aacr-2024-annual-meeting/) - [Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window](https://www.synthekine.com/news/synthekine-presents-preclinical-data-at-sitc-38th-annual-meeting-demonstrating-its-il-12-partial-agonist-stk-026-significantly-expands-therapeutic-window/) - [Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases](https://www.synthekine.com/news/synthekine-announces-strategic-collaboration-with-sanofi-to-develop-selective-il-10-agonists-for-treatment-of-inflammatory-diseases/) - [Synthekine Appoints Geoff Nosrati, Ph.D., as Chief Business Officer and Announces Executive Leadership Changes](https://www.synthekine.com/news/synthekine-appoints-geoff-nosrati-ph-d-as-chief-business-officer-and-announces-executive-leadership-changes/) - [First Patient Dosed in Phase 1b Clinical Trial of Synthekine’s α/β Biased IL-2, STK-012, for Treatment of Solid Tumors](https://www.synthekine.com/news/first-patient-dosed-in-phase-1b-clinical-trial-of-synthekines-α-β-biased-il-2-stk-012-for-treatment-of-solid-tumors/) - [Synthekine Announces Presentations at AACR 2023 Annual Meeting Showcasing Next Series of Oncology Programs](https://www.synthekine.com/news/synthekine-announces-presentations-at-aacr-2023-annual-meeting-showcasing-next-series-of-oncology-programs/) - [Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics](https://www.synthekine.com/news/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics/) - [Fierce Biotech names Synthekine as one of its “Fierce 15” Biotech Companies of 2022](https://www.synthekine.com/news/fierce-biotech-names-synthekine-as-one-of-its-fierce-15-biotech-companies-of-2022/) - [Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors](https://www.synthekine.com/news/synthekine-doses-first-patient-in-phase-1-clinical-trial-of-il-2-partial-agonist-stk-012-for-treatment-of-solid-tumors/) - [Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting](https://www.synthekine.com/news/synthekine-announces-multiple-poster-presentations-showcasing-its-three-distinct-cytokine-engineering-platforms-at-american-association-for-cancer-research-aacr-2022-annual-meeting/) - [Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System](https://www.synthekine.com/news/2021/synthekine-announces-publication-of-preclinical-data-demonstrating-in-vivo-control-of-cd19-car-t-cells-with-its-orthogonal-il-2-system/) - [Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases](https://www.synthekine.com/news/2020/synthekine-launches-with-82-million-series-a-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics-optimized-for-cancer-and-autoimmune-diseases/) - [Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T](https://www.synthekine.com/news/2020/synthekine-presents-data-at-american-society-of-hematology-annual-meeting-showing-orthogonal-il-2-ligand-drives-deeper-and-more-durable-response-of-cd-19-car-t/) - [Synthekine Strengthens Leadership with Board of Directors Expansion and Scientific Advisory Board Formation](https://www.synthekine.com/news/2021/synthekine-strengthens-leadership-with-board-of-directors-expansion-and-scientific-advisory-board-formation/) - [Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities](https://www.synthekine.com/news/2021/synthekine-presents-data-at-aacr-annual-meeting-2021-demonstrating-selective-il-2-partial-agonist-stk-012-promotes-anti-tumor-response-without-related-toxicities/) - [Synthekine Licenses Additional Cytokine Programs](https://www.synthekine.com/news/2021/synthekine-licenses-additional-cytokine-programs/) - [Synthekine Appoints Internationally Recognized Cancer Immunotherapy Leader Naiyer Rizvi, M.D., as Chief Medical Officer](https://www.synthekine.com/news/2021/synthekine-appoints-internationally-recognized-cancer-immunotherapy-leader-naiyer-rizvi-m-d-as-chief-medical-officer/) - [Synthekine Expands Board of Directors, Management Team and Scientific Advisory Board with New Key Appointments](https://www.synthekine.com/news/2021/synthekine-expands-board-of-directors-management-team-and-scientific-advisory-board-with-new-key-appointments/) - [Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform](https://www.synthekine.com/news/2021/synthekine-announces-107-5-million-oversubscribed-series-b-financing-to-support-lead-programs-to-clinical-proof-of-concept-advance-preclinical-programs-and-platform/) - [Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors](https://www.synthekine.com/news/2021/synthekine-advances-il-2-partial-agonist-stk-012-into-clinical-investigation-for-treatment-of-solid-tumors/) - [Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform](https://www.synthekine.com/news/2021/synthekine-establishes-collaboration-with-merck-to-develop-therapeutic-candidates-using-its-proprietary-surrogate-cytokine-agonist-platform/) ## Pages - [Home](https://www.synthekine.com/) - Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease. - [Careers](https://www.synthekine.com/careers/) - Join us as we adventure beyond conventional scientific thinking. At Synthekine, we believe our open mindset — questioning dogma and constantly re-examining the data — is instrumental in discovering and developing transformative medicines. See what it’s like to be a member of the Synthekine team. - [About Us](https://www.synthekine.com/about-us/) - A company applying distinct protein engineering platforms to develop immunotherapies designed to unlock the full efficacy potential of cytokines while avoiding toxicities associated with their pleiotropy. - [testing-246135796135](https://www.synthekine.com/testing-246135796135/) - [News](https://www.synthekine.com/news/) - We’ve been busy. Catch up on the latest news, updates and happenings at Synthekine. - [Footer](https://www.synthekine.com/footer/) - [Privacy Policy](https://www.synthekine.com/privacy-policy/) - [For Patients](https://www.synthekine.com/for-patients/) - Harnessing the Potential of Cytokines. We are applying multiple protein engineering platforms to create a pipeline of cytokine therapeutics for cancer and inflammatory disease. - [Our Pipeline](https://www.synthekine.com/our-pipeline/) - A Different Kind of Cytokine Therapy. We are building a pipeline of novel immunotherapies that we believe will deliver on the promise of cytokine therapeutics for patients with cancer and inflammatory diseases. - [Our Platforms](https://www.synthekine.com/our-platforms/) - Harnessing the Potential of Cytokines. We are applying multiple protein engineering platforms to create a pipeline of cytokine therapeutics for cancer and inflammatory disease. - [Contact](https://www.synthekine.com/contact/) - Get in touch with a member of the Synthekine team today. ## Portfolio Items - [Pablo Cagnoni, M.D.](https://www.synthekine.com/leadership/pablo-cagnoni-m-d/) - [Susan Molineaux, Ph.D.](https://www.synthekine.com/leadership/susan-molineaux-ph-d/) - [Nils Lonberg, Ph.D.](https://www.synthekine.com/leadership/nils-lonberg-ph-d/) - [Susan Molineaux, Ph.D.](https://www.synthekine.com/leadership/susan-molineaux/) - Chief Executive Officer - [Iris Sison](https://www.synthekine.com/leadership/iris-sison/) - [Anita Mehta-Damani, Ph.D.](https://www.synthekine.com/leadership/anita-mehta-damani-ph-d/) - [Naiyer Rizvi, M.D.](https://www.synthekine.com/leadership/naiyer-rizvi-m-d/) - [Robin Knifsend](https://www.synthekine.com/leadership/robin-knifsend/) - [John A. Orwin, MBA](https://www.synthekine.com/leadership/john-a-orwin-mba/) - [Craig Parker, MBA](https://www.synthekine.com/leadership/craig-parker-mba/) - [Richard Murphy, J.D.](https://www.synthekine.com/leadership/richard-murphy-j-d/) - [Christopher Garten](https://www.synthekine.com/leadership/christopher-garten/) - [Alex Azrilevich, PharmD](https://www.synthekine.com/leadership/alex-azrilevich/) - [Geoff Nosrati, Ph.D.](https://www.synthekine.com/leadership/geoff-nosrati-ph-d/) - [Gregory Yedinak](https://www.synthekine.com/leadership/gergory-yedinak/) - [Martin Oft, M.D.](https://www.synthekine.com/leadership/martin-oft-m-d/) - [Julie Grant, MBA, MPHIL](https://www.synthekine.com/leadership/julie-grant-mba-mphil/) - [Srinivas Akkaraju, M.D., Ph.D.](https://www.synthekine.com/leadership/srinivas-akkaraju-m-d-ph-d/) ## Categories - [2020](https://www.synthekine.com/category/news/2020/) - [2021](https://www.synthekine.com/category/news/2021/) - [news](https://www.synthekine.com/category/news/) - [2022](https://www.synthekine.com/category/news/2022/) - [2023](https://www.synthekine.com/category/news/2023/) - [2024](https://www.synthekine.com/category/news/2024/) - [careers](https://www.synthekine.com/category/careers/) - [2025](https://www.synthekine.com/category/news/2025/) - [2026](https://www.synthekine.com/category/news/2026/) ## Portfolio Categories - [Management](https://www.synthekine.com/leadership/management/) - [BOD](https://www.synthekine.com/leadership/bod/)